MetaCap

Immatics N.V. (IMTX) vs Vor Biopharma (VOR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Vor Biopharma (VOR) has outperformed Immatics N.V. (IMTX) over the past year, gaining 157.6% versus a loss of 43.4%. Over five years, IMTX leads with a -48.6% price change compared with -92.0% for VOR. Vor Biopharma is the larger company by market cap ($1.18 billion vs $878.6 million), about 1.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMTX-43.43%VOR+157.58%
+251%+97%-57%
Nov 21, 20251 yearNov 20, 2026
IMTX-51.47%VOR-92.93%
+19%-43%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMTX versus VOR key metrics
MetricIMTXVOR
Share price$5.77$19.19
Market cap$878.58M$1.18B
1-day change-3.03%+3.62%
YTD return-45.05%+46.71%
1-year return-43.43%+157.58%
5-year return-48.57%-92.00%
P/E ratio (TTM)—0.06
EPS (TTM)$-1.95$300.56
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-695.98M
52-week high$12.41$26.00
52-week low$5.72$7.21
Distance from 52-week high-53.51%-26.19%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+176.78%+103.23%
Average volume962.74K945.67K
Shares outstanding152.27M61.43M
Employees72176
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • VOR has outperformed IMTX by 201.0 percentage points over the past year.

About Immatics N.V.

IMTX stock →

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 721 employees

About Vor Biopharma

VOR stock →

Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 76 employees

IMTX vs VOR FAQ

Which is bigger, Immatics N.V. or Vor Biopharma?

Vor Biopharma (VOR) is larger, with a market capitalization of $1.18B compared with $878.58M for Immatics N.V. (IMTX).

Which stock has performed better over the past year, IMTX or VOR?

VOR returned +157.58% over the past 12 months, compared with -43.43% for IMTX (price return, excluding dividends). Past performance does not predict future results.

Are Immatics N.V. and Vor Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons